Dr. Locke on the Results of the ZUMA-7 Trial in Relapsed/Refractory Large B-Cell Lymphoma

Frederick Locke, MD, vice chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy Program, co-leader, Immuno-Oncology, Moffitt Cancer Center, discusses the results of the phase 3 ZUMA-7 trial (NCT03391466) in patients with large B-cell lymphoma ​(LBCL) that were presented at the 2021 ASH Annual Meeting & Exposition.

The primary end point of the ZUMA-7 trial was event-free survival (EFS), defined as time from randomization to the earliest date of disease progression including death due to any cause or commencement of different anti-lymphoma therapy, Locke says. The data showed that over 90% of patients randomized received CAR T-cell therapy with axicabtagene ciloleucel (axi-cel; Yescarta), whereas about 30% of patients received a definitive autologous hematopoietic stem cell transplant, Locke explained.

The findings from the study demonstrated a median EFS of 8.3 months with axi-cel vs 2 months with standard of care in patients with relapsed/refractory LBCL, Locke continues. Notably, the 24-month EFS rate was 40.5% compared with 16.3%, respectively. This means that at 2 years after randomization, over 40% of patients who received axi-cel arm did not require additional therapy and remained in remission, Locke concludes.